265 related articles for article (PubMed ID: 9476925)
1. Thallium-201 uptake with negative iodine-131 scintigraphy and serum thyroglobulin in metastatic oxyphilic papillary thyroid carcinoma.
Harder W; Lind P; Molnar M; Mikosch P; Gomez I; Gallowitsch HJ; Kresnik E; Unterweger O; Dinges HP
J Nucl Med; 1998 Feb; 39(2):236-8. PubMed ID: 9476925
[TBL] [Abstract][Full Text] [Related]
2. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
3. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
Oyen WJ; Verhagen C; Saris E; van den Broek WJ; Pieters GF; Corsten FH
J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
[TBL] [Abstract][Full Text] [Related]
4. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
5. Thallium-201 scintigraphy in differentiated thyroid cancer: comparison with radioiodine scintigraphy and serum thyroglobulin determinations.
Ramanna L; Waxman A; Braunstein G
J Nucl Med; 1991 Mar; 32(3):441-6. PubMed ID: 2005453
[TBL] [Abstract][Full Text] [Related]
6. The role of iodine-131 and thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma.
Dadparvar S; Krishna L; Brady LW; Slizofski WJ; Brown SJ; Chevres A; Micaily B
Cancer; 1993 Jun; 71(11):3767-73. PubMed ID: 8490927
[TBL] [Abstract][Full Text] [Related]
7. 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma.
Ng DC; Sundram FX; Sin AE
J Nucl Med; 2000 Apr; 41(4):631-5. PubMed ID: 10768563
[TBL] [Abstract][Full Text] [Related]
8. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
9. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy.
Seabold JE; Gurll N; Schurrer ME; Aktay R; Kirchner PT
J Nucl Med; 1999 Sep; 40(9):1434-40. PubMed ID: 10492361
[TBL] [Abstract][Full Text] [Related]
11. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma.
Lubin E; Mechlis-Frish S; Zatz S; Shimoni A; Segal K; Avraham A; Levy R; Feinmesser R
J Nucl Med; 1994 Feb; 35(2):257-62. PubMed ID: 8294995
[TBL] [Abstract][Full Text] [Related]
12. Thallium-201 and iodine-131 scintigraphy in differentiated thyroid carcinoma.
Lorberboym M; Murthy S; Mechanick JI; Bergman D; Morris JC; Kim CK
J Nucl Med; 1996 Sep; 37(9):1487-91. PubMed ID: 8790199
[TBL] [Abstract][Full Text] [Related]
13. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
Ringel MD; Balducci-Silano PL; Anderson JS; Spencer CA; Silverman J; Sparling YH; Francis GL; Burman KD; Wartofsky L; Ladenson PW; Levine MA; Tuttle RM
J Clin Endocrinol Metab; 1999 Nov; 84(11):4037-42. PubMed ID: 10566646
[TBL] [Abstract][Full Text] [Related]
14. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma.
Alnafisi NS; Driedger AA; Coates G; Moote DJ; Raphael SJ
J Nucl Med; 2000 Jun; 41(6):1010-5. PubMed ID: 10855626
[TBL] [Abstract][Full Text] [Related]
15. Complementary role of whole body scan and serum thyroglobulin determination in the follow-up of differentiated thyroid carcinoma.
Ronga G; Fiorentino A; Fragasso G; Fringuelli FM; Todino V
Ital J Surg Sci; 1986; 16(1):11-5. PubMed ID: 3087907
[TBL] [Abstract][Full Text] [Related]
16. Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases.
Filesi M; Signore A; Ventroni G; Melacrinis FF; Ronga G
J Nucl Med; 1998 Sep; 39(9):1542-6. PubMed ID: 9744339
[TBL] [Abstract][Full Text] [Related]
17. Follow-up study of postoperative patients with thyroid cancer by thallium-201 scintigraphy and serum thyroglobulin measurement.
Iida Y; Hidaka A; Hatabu H; Kasagi K; Konishi J
J Nucl Med; 1991 Nov; 32(11):2098-100. PubMed ID: 1941144
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic capabilities of I-131, TI-201, and Tc-99m-MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy.
Fujie S; Okumura Y; Sato S; Akaki S; Katsui K; Himei K; Takemoto M; Kanazawa S
Acta Med Okayama; 2005 Jun; 59(3):99-107. PubMed ID: 16049563
[TBL] [Abstract][Full Text] [Related]
19. Serum thyroglobulin concentrations and whole-body radioiodine scan in follow-up of differentiated thyroid cancer after thyroid ablation.
Ng Tang Fui SC; Hoffenberg R; Maisey MN; Black EG
Br Med J; 1979 Aug; 2(6185):298-300. PubMed ID: 476434
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
Valli N; Catargi B; Ronci N; Leccia F; Guyot M; Roger P; Ducassou D; Tabarin A
Thyroid; 1999 Jun; 9(6):583-9. PubMed ID: 10411121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
